{"id":48360,"date":"2022-09-14T14:01:52","date_gmt":"2022-09-14T12:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/"},"modified":"2022-09-14T14:01:52","modified_gmt":"2022-09-14T12:01:52","slug":"iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/","title":{"rendered":"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Biotechnology Virtual Private Company Symposium on Wednesday, September 21, 2022 at 1:30 p.m. ET (10:30 a.m. PT).\n<\/p>\n

<\/a><\/p>\n

\nAbout IconOVir<\/b>\n<\/p>\n

\nIconOVir is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. IconOVir\u2019s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O\u2019Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients. For more information, please visit www.iconovir.com<\/a> and follow IconOVir on LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany Contact:<\/b>
Amy Thai
\n
amy.thai@iconovir.com<\/a>
1-858-293-5600\n<\/p>\n

\nInvestor Contact:<\/b>
Hannah Deresiewicz
\n
Stern Investor Relations, Inc.
\n
hannah.deresiewicz@sternir.com<\/a>
1-212-362-1200\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Biotechnology Virtual Private Company Symposium on … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48360","6":"format-standard","7":"category-industry"},"yoast_head":"\nIconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Biotechnology Virtual Private Company Symposium on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T12:01:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220914005016\/en\/1474985\/21\/IconOVir_Bio_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium\",\"datePublished\":\"2022-09-14T12:01:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/\"},\"wordCount\":187,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005016\\\/en\\\/1474985\\\/21\\\/IconOVir_Bio_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/\",\"name\":\"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005016\\\/en\\\/1474985\\\/21\\\/IconOVir_Bio_Logo.jpg\",\"datePublished\":\"2022-09-14T12:01:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005016\\\/en\\\/1474985\\\/21\\\/IconOVir_Bio_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005016\\\/en\\\/1474985\\\/21\\\/IconOVir_Bio_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/","og_locale":"en_US","og_type":"article","og_title":"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Biotechnology Virtual Private Company Symposium on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-14T12:01:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220914005016\/en\/1474985\/21\/IconOVir_Bio_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium","datePublished":"2022-09-14T12:01:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/"},"wordCount":187,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005016\/en\/1474985\/21\/IconOVir_Bio_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/","url":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/","name":"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005016\/en\/1474985\/21\/IconOVir_Bio_Logo.jpg","datePublished":"2022-09-14T12:01:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220914005016\/en\/1474985\/21\/IconOVir_Bio_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220914005016\/en\/1474985\/21\/IconOVir_Bio_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/iconovir-bio-to-present-at-ubs-biotechnology-virtual-private-company-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48360"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48360\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}